drugset / Trial / NCT00186108

A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

NCT00186108

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.

Timeline

Start
2002-10
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinalone Small molecule Oral

Indications